Effects of lorcaserin (Belviq^®) on nicotine- and food-maintained responding in non-human primates.

ABSTRACT:

Background

Accumulating evidence suggests that the FDA-approved serotonin 5-HT_2C receptor agonist, lorcaserin (Belviq^®), may be a promising candidate for the management of substance use disorders, including nicotine addiction. The present study was conducted to determine the efficacy and selectivity of acute or continuous lorcaserin treatment for decreasing the reinforcing effects of nicotine in a primate species.

Methods

Adult rhesus monkeys (n=4) with a history of nicotine self-administration (>2years) responded for injections of nicotine (0.32-100μg/kg IV) or food pellets under a fixed-ratio schedule of reinforcement during daily 100-min sessions. When responding was stable, lorcaserin was administered either as an acute pretreatment (0.1-1.0mg/kg, I

SUBMITTER: Jacobs DS 

PROVIDER: S-EPMC5857383 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature